Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2018-02-09 Major Shareholding Noti…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-09 English
Regulatory Filings 2018
Regulatory Filings Classification · 90% confidence The provided document text appears to be an encoded or binary file content (e.g., base64 or uuencoded data) rather than readable text. There are no discernible keywords, regulatory headers, form names, fiscal period dates, or document titles that can be extracted from the text. The document length is 15,000 characters, which is substantial, but without readable content or metadata indicating the nature of the filing, it is impossible to classify it as a specific report type such as Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or others. Given the lack of identifiable information and the fallback rule, the appropriate classification is Regulatory Filings (RNS), which serves as a catch-all category for filings that do not fit other specific categories.
2018-02-07 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 24, 2018, by Ligand Pharmaceuticals Incorporated. The content focuses on the departure, election, and appointment of directors or officers, specifically detailing base salary increases, bonuses, and promotions of named executive officers. There is no financial statement or comprehensive financial data presented, nor is it an earnings release or annual report. The primary subject is changes and compensation adjustments related to senior management. According to the filing definitions, this fits best under 'Board/Management Information (MANG)' which covers announcements of changes in the company's board of directors or senior management. The document length is 4031 characters, which is short but contains substantive information about management changes and compensation, not just an announcement of a report or certification. Therefore, the classification is MANG with high confidence.
2018-01-29 English
PRIMARY DOCUMENT
Director's Dealing
2018-01-26 English
PRIMARY DOCUMENT
Director's Dealing
2018-01-23 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-01-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.